Casadei Gardini Andrea, Santini Daniele, Aprile Giuseppe, Silvestris Nicola, Felli Emanuele, Foschi Francesco Giuseppe, Ercolani Giorgio, Marisi Giorgia, Valgiusti Martina, Passardi Alessandro, Puzzoni Marco, Silletta Marianna, Brunetti Oronzo, Cardellino Giovanni Gerardo, Frassineti Giovanni Luca, Scartozzi Mario
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Medical Oncology Department, University Campus Bio-Medico, Via Álvaro del Portillo, Rome, Italy.
Oncotarget. 2017 Jul 22;8(39):66699-66708. doi: 10.18632/oncotarget.19449. eCollection 2017 Sep 12.
Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage, although the combination of TACE with sorafenib may theoretically benefit HCC patients in intermediate stage. Owing to the significant antiangiogenic effect of sorafenib and the limitation of TACE, it is rational to combine them. Though the strategy of combining TACE and sorafenib has been increasingly used in patients with unresectable HCC but the current evidence is controversial and its clinical role has not been determined yet. In first-line therapy, patients receiving sorafenib had increased overall survival and progression free survival. Therefore several antiangiogenic agents have entered clinical studies on HCC, many with negative results. This review discusses the current drug development for patients with HCC and role of TACE plus sorafenib.
经动脉化疗栓塞术（TACE）是中期肝癌的标准治疗方法，尽管从理论上讲，TACE与索拉非尼联合使用可能会使中期肝癌患者受益。由于索拉非尼具有显著的抗血管生成作用以及TACE存在局限性，将二者联合使用是合理的。虽然TACE与索拉非尼联合的策略已越来越多地应用于不可切除肝癌患者，但目前的证据存在争议，其临床作用尚未确定。在一线治疗中，接受索拉非尼治疗的患者总生存期和无进展生存期有所延长。因此，几种抗血管生成药物已进入肝癌的临床研究，许多研究结果为阴性。本综述讨论了目前针对肝癌患者的药物研发情况以及TACE联合索拉非尼的作用。
